Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BL-M14D1 injection combined with atezolizumab in extensive-stage small cell lung cancer
CTR20262337Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BL-M14D1, atezolizumab in small cell lung cancer (SCLC), sponsored by Biokin Pharmaceutical. Started Jul 2026; status: active.
02
Drugs
BL-M14D1atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20262337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262337.